Recent Development of the Second and Third Generation Irreversible Epidermal Growth Factor Receptor Inhibitors
1School of Chemistry and Pharmaceutical Engineering, Qilu University of Technology, 3501 Daxue Road, Jinan, 250353, P. R. China.
Abstract:
Recent reports suggested that essential directions for new lung cancer, breast carcinoma therapies, as well as the roomier realm of targeted cancer therapies were provided through targeting the epidermal growth factor receptor (EGFR). Patients who carrying non-small cell lung carcinoma (NSCLC) with activating mutations in EGFR initially respond well to the EGFR inhibitors erlotinib and gefitinib, which were located the active site of the EGFR kinase and designed to act as competitive inhibitors of combining with the ATP. However, patients who were treated with the erlotinib and gefitinib will relapse because of the emergence of drug-resistant mutations, with T790M mutations accounting for approximately 60% of all resistance. In order to overcome drug resistance, Pharmaceutical chemistry experts recently devoted great endeavors to the development of second-generation irreversible selective inhibitors which covalently modify Cys797 or Cys773 at the ATP binding cleft. Nevertheless, these inhibitors have not reached ideal effect of experts in patients with T790M positive mutation and apparently because of the dose-limiting toxicities associated with inhibition of wild type EGFR. A novel class of 'third generation' EGFR TKIs have been developed that is sensitising and T790M mutant-specific whilst sparing WT EGFR, representing a significant breakthrough in the treatment in NSCLC patients with acquired resistance harboring these genotypes. Herein, we provides an overview of the second and third generation inhibitors currently approved, in clinical trial and also encompasses novel structures of discovery. This review mainly focuses on drug resistance, their mechanisms of action, development of structure-activity relationships and binding modes.
Insights
Second and third-generation epidermal growth factor receptor (EGFR) inhibitors offer new hope for non-small cell lung cancer (NSCLC) patients. These advanced therapies target resistant mutations like T790M while sparing healthy cells, overcoming previous treatment limitations.
Area of Science:
- Oncology
- Pharmacology
- Molecular Biology
Background:
- Targeting the epidermal growth factor receptor (EGFR) has been crucial for developing therapies for lung and breast cancers.
- First-generation EGFR inhibitors (erlotinib, gefitinib) are effective against non-small cell lung cancer (NSCLC) with activating EGFR mutations but lead to acquired resistance, primarily through T790M mutations.
- Second-generation inhibitors were developed to overcome resistance but showed limited efficacy and dose-limiting toxicities due to wild-type EGFR inhibition.
Purpose of the Study:
- To provide an overview of second and third-generation EGFR inhibitors for NSCLC treatment.
- To discuss mechanisms of drug resistance, structure-activity relationships, and binding modes.
- To highlight the development of novel EGFR-targeted therapies.
Main Methods:
- Review of literature on EGFR inhibitors, focusing on second and third-generation compounds.
- Analysis of drug resistance mechanisms, particularly T790M mutations in NSCLC.
- Exploration of structure-activity relationships and binding modes of novel inhibitors.
Main Results:
- Second-generation inhibitors showed promise but faced challenges with T790M-positive mutations and toxicity.
- Third-generation EGFR TKIs have been developed that are mutant-specific (T790M) and spare wild-type EGFR, representing a significant advancement.
- These novel inhibitors offer improved efficacy and safety profiles for NSCLC patients with acquired resistance.
Conclusions:
- Third-generation EGFR TKIs represent a breakthrough in treating NSCLC with acquired resistance, offering targeted therapy for specific genotypes.
- Continued research into novel structures and understanding resistance mechanisms is essential for further therapeutic advancements.
- These inhibitors improve treatment outcomes for NSCLC patients with EGFR mutations, particularly the T790M resistance mutation.
More Related Videos
09:38Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
08:28Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells
Published on: May 9, 2025
Related Concept Videos
02:38Mitogens and the Cell Cycle
01:19Clinical Applications of Epidermal Stem Cells
01:12Renewal of Skin Epidermal Stem Cells
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
01:27Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include:
01:26Receptor Tyrosine Kinases